Deciphera Pharmaceuticals, Inc. (DCPH)
(Delayed Data from NSDQ)
$23.59 USD
+0.67 (2.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $23.47 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.59 USD
+0.67 (2.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $23.47 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -15.93% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Deciphera's NDA for GIST Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -7.56% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?
by Zacks Equity Research
Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.
Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.
Deciphera Pharmaceuticals, Inc. (DCPH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
by Zacks Equity Research
Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.
Implied Volatility Surging for Deciphera (DCPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Deciphera (DCPH) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) needs investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Deciphera Pharmaceuticals (DCPH) stock based on the movements in the options market lately.
Deciphera Pharmaceuticals Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Deciphera Pharmaceuticals.
Company News For Jun 5, 2018
by Zacks Equity Research
Companies in the news are: GHDX,BAYN.DE, NKTR,DCPH